Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused studies following positive Phase 1 clinical results. The company reported that Phase 1 studies in healthy volunteers demonstrated a favorable safety profile, with the therapy generally well tolerated, supporting progression into Phase 2 trials. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
LUCID-MS is designed to target demyelination and protect or restore myelin integrity. Unlike many existing treatments that rely primarily on immune modulation, Quantum BioPharma believes LUCID-MS may offer a differentiated, potentially first-in-class approach by directly addressing myelin loss and neurodegeneration. The company is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists.
Multiple sclerosis is a chronic neurodegenerative disease in which the immune system attacks the myelin sheath surrounding nerve fibers, leading to communication disruptions between the brain and the rest of the body. Current therapies often focus on modulating the immune response but do not effectively repair or prevent myelin damage. If successful, LUCID-MS could represent a significant advancement in treating the underlying mechanisms of MS, potentially slowing or reversing disease progression.
Quantum BioPharma, through its wholly owned subsidiary Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models. The company is building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders, as well as alcohol misuse disorders.
The implications of this announcement are substantial for the estimated 2.8 million people worldwide living with multiple sclerosis. A therapy that can directly protect and restore myelin could alter the treatment landscape, offering hope for disease modification rather than just symptom management. For the biopharmaceutical industry, Quantum BioPharma’s progress underscores a growing focus on neuroprotective strategies beyond immune modulation.
For more information on Quantum BioPharma, visit the company’s newsroom at https://ibn.fm/QNTM. The full article discussing this development can be viewed at https://ibn.fm/AUhNl.
